Regulatory requirements of the European Medicines Agency for evaluation of bioequivalence of modified-release medicinal products
There are no specific requirements and recommendations in the Russian Federation for evaluation of bioequivalence of modified-release medicinal products. Until recently, modified-release products were regulated in a similar manner as immediate-release products, which is unacceptable considering the...
Saved in:
| Main Authors: | D. P. Romodanovsky, N. N. Eremenko, D. V. Goryachev |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)
2019-03-01
|
| Series: | Регуляторные исследования и экспертиза лекарственных средств |
| Subjects: | |
| Online Access: | https://www.vedomostincesmp.ru/jour/article/view/218 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PLANNING AND EVALUATION OF BIOEQUIVALENCE STUDIES OF ATAZANAVIR PRODUCTS
by: N. E. Uvarova, et al.
Published: (2018-12-01) -
Problems of bioanalytical part of bioequivalence studies of drugs in Russia
by: A. L. Khokhlov, et al.
Published: (2014-04-01) -
Bioequivalence study of generic nirmatrelvir in healthy volunteers
by: R. A. Oseshnyuk, et al.
Published: (2023-05-01) -
Effects of Food on the Bioavailability of Medicinal Products in Bioequivalence Studies: A Comparative Analysis of Regulatory Documents
by: N. N. Eremenko
Published: (2025-04-01) -
A COMPARATIVE ANALYSIS OF BIOEQUIVALENCE, CLINICAL EFFICACY AND SAFETY OF GENERIC VERSUS ORIGINAL CYCLOSPORINE AFTER KIDNEY TRANSPLANTATION
by: E. S. Stolyarevich, et al.
Published: (2015-04-01)